Literature DB >> 23644038

Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy.

Jay C Fournier1, Robert J DeRubeis, Steven D Hollon, Robert Gallop, Richard C Shelton, Jay D Amsterdam.   

Abstract

Cognitive therapy and antidepressant medications are effective treatments for depression, but little is known about their relative efficacy in reducing individual depressive symptoms. Using data from a recent clinical trial comparing cognitive therapy, antidepressant medication, and placebo in the treatment of moderate-to-severe depression, we examined whether there was a relative advantage of any treatment in reducing the severity of specific depressive symptom clusters. The sample consisted of 231 depressed outpatients randomly assigned to: cognitive therapy for 16 weeks (n = 58); paroxetine treatment for 16 weeks (n = 116); or pill placebo for 8 weeks (n = 57). Differential change in five subsets of depressive symptoms was examined: mood, cognitive/suicide, anxiety, typical-vegetative, and atypical-vegetative symptoms. Medication led to a greater reduction in cognitive/suicide symptoms relative to placebo by 4 weeks, and both active treatments reduced these symptoms more than did placebo by 8 weeks. Cognitive therapy reduced the atypical-vegetative symptoms more than placebo by 8 weeks and more than medications throughout the trial. These findings suggest that medications and cognitive therapy led to different patterns of response to specific symptoms of depression and that the general efficacy of these two well-validated treatments may be driven in large part by changes in cognitive or atypical-vegetative symptoms.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23644038      PMCID: PMC3711944          DOI: 10.1016/j.brat.2013.03.010

Source DB:  PubMed          Journal:  Behav Res Ther        ISSN: 0005-7967


  31 in total

1.  Mode-specific effects among three treatments for depression.

Authors:  S D Imber; P A Pilkonis; S M Sotsky; I Elkin; J T Watkins; J F Collins; M T Shea; W R Leber; D R Glass
Journal:  J Consult Clin Psychol       Date:  1990-06

2.  Causal mediation of change in treatment for depression: discriminating between nonspecificity and noncausality.

Authors:  S D Hollon; R J DeRubeis; M D Evans
Journal:  Psychol Bull       Date:  1987-07       Impact factor: 17.737

Review 3.  Comparative studies on the efficacy of psychotherapy, pharmacotherapy, and their combination in depression: was adequate pharmacotherapy provided?

Authors:  G B Meterissian; J Bradwejn
Journal:  J Clin Psychopharmacol       Date:  1989-10       Impact factor: 3.153

4.  Clinical and demographic features of mood disorder subtypes.

Authors:  Alessandro Serretti; Laura Mandelli; Enrico Lattuada; Cristina Cusin; Enrico Smeraldi
Journal:  Psychiatry Res       Date:  2002-11-15       Impact factor: 3.222

Review 5.  The Hamilton Depression Rating Scale: has the gold standard become a lead weight?

Authors:  R Michael Bagby; Andrew G Ryder; Deborah R Schuller; Margarita B Marshall
Journal:  Am J Psychiatry       Date:  2004-12       Impact factor: 18.112

6.  Atypical depression: a review of diagnosis and treatment.

Authors:  S F Aarons; A J Frances; J J Mann
Journal:  Hosp Community Psychiatry       Date:  1985-03

7.  How does cognitive therapy work? Cognitive change and symptom change in cognitive therapy and pharmacotherapy for depression.

Authors:  R J DeRubeis; M D Evans; S D Hollon; M J Garvey; W M Grove; V B Tuason
Journal:  J Consult Clin Psychol       Date:  1990-12

Review 8.  Paroxetine: a selective serotonin reuptake inhibiting antidepressant.

Authors:  C F Caley; S S Weber
Journal:  Ann Pharmacother       Date:  1993-10       Impact factor: 3.154

9.  Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors.

Authors:  M E Thase; E Frank; A G Mallinger; T Hamer; D J Kupfer
Journal:  J Clin Psychiatry       Date:  1992-01       Impact factor: 4.384

10.  Differential effects of cognitive therapy and pharmacotherapy on depressive symptoms.

Authors:  A J Rush; M Kovacs; A T Beck; J Weissenburger; S D Hollon
Journal:  J Affect Disord       Date:  1981-09       Impact factor: 4.839

View more
  11 in total

1.  Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder.

Authors:  Boadie W Dunlop; Steven P Cole; Charles B Nemeroff; Helen S Mayberg; W Edward Craighead
Journal:  J Affect Disord       Date:  2017-12-27       Impact factor: 4.839

2.  Mechanisms of symptom reduction in a combined treatment for comorbid posttraumatic stress disorder and alcohol dependence.

Authors:  Carmen P McLean; Yi-Jen Su; Edna B Foa
Journal:  J Consult Clin Psychol       Date:  2015-06

3.  Functional Impairment and Changes in Depression Subtypes for Women in STAR*D: A Latent Transition Analysis.

Authors:  Christine M Ulbricht; Anthony J Rothschild; Kate L Lapane
Journal:  J Womens Health (Larchmt)       Date:  2015-10-21       Impact factor: 2.681

4.  Atypical depression and double depression predict new-onset cardiovascular disease in U.S. adults.

Authors:  Stephanie M Case; Manisha Sawhney; Jesse C Stewart
Journal:  Depress Anxiety       Date:  2017-06-22       Impact factor: 6.505

5.  Trajectories of individual depressive symptoms in adolescents: gender and family relationships as predictors.

Authors:  Chrystyna D Kouros; Judy Garber
Journal:  Dev Psychol       Date:  2014-10-20

6.  The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis.

Authors:  Lynn Boschloo; Ella Bekhuis; Erica S Weitz; Mirjam Reijnders; Robert J DeRubeis; Sona Dimidjian; David L Dunner; Boadie W Dunlop; Ulrich Hegerl; Steven D Hollon; Robin B Jarrett; Sidney H Kennedy; Jeanne Miranda; David C Mohr; Anne D Simons; Gordon Parker; Frank Petrak; Stephan Herpertz; Lena C Quilty; A John Rush; Zindel V Segal; Jeffrey R Vittengl; Robert A Schoevers; Pim Cuijpers
Journal:  World Psychiatry       Date:  2019-06       Impact factor: 49.548

7.  Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study.

Authors:  Christian A Webb; Madhukar H Trivedi; Zachary D Cohen; Daniel G Dillon; Jay C Fournier; Franziska Goer; Maurizio Fava; Patrick J McGrath; Myrna Weissman; Ramin Parsey; Phil Adams; Joseph M Trombello; Crystal Cooper; Patricia Deldin; Maria A Oquendo; Melvin G McInnis; Quentin Huys; Gerard Bruder; Benji T Kurian; Manish Jha; Robert J DeRubeis; Diego A Pizzagalli
Journal:  Psychol Med       Date:  2018-07-02       Impact factor: 7.723

8.  Adding cognitive therapy to antidepressant medications decreases suicidal ideation.

Authors:  Gabriela K Khazanov; Colin Xu; Steven D Hollon; Robert J DeRubeis; Michael E Thase
Journal:  J Affect Disord       Date:  2020-12-08       Impact factor: 4.839

9.  Specific Pharmacological Effects of Paroxetine Comprise Psychological but Not Somatic Symptoms of Depression.

Authors:  Benjamin D Schalet; Tony Z Tang; Robert J DeRubeis; Steven D Hollon; Jay D Amsterdam; Richard C Shelton
Journal:  PLoS One       Date:  2016-07-20       Impact factor: 3.240

Review 10.  Atypical depression: current perspectives.

Authors:  Dorota Łojko; Janusz K Rybakowski
Journal:  Neuropsychiatr Dis Treat       Date:  2017-09-20       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.